![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Denovo Biopharma Gains Global Licensure to Wuzhong’s Oncology Drug
Denovo Biopharma Gains Global Licensure to Wuzhong’s Oncology Drug
![Denovo Biopharma Logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/DenovoBiopharma-Logo.gif?t=1607661738&width=430)
December 11, 2020
Denovo Biopharma has acquired the global rights, outside China, to oncology drug endostatin from Chinese drugmaker Wuzhong Pharmaceutical.
Endostatin, which Denovo has renamed DB108, is a recombinant protein drug meant to inhibit tumor growth by blocking the production of new blood vessels. In a phase 3 study, Wuzhong evaluated DB108 for nonsmall-cell lung cancer, where it was said to significantly improve progression-free survival in participants.
San Diego, Calif.-based Denovo said the deal enables its “expansion into the field of protein therapeutics.”
Upcoming Events
-
21Oct